Bayer ’s Phase II trial for MPM drug fails to meet primary endpoint

Bayer ’s Phase II clinical trial of its oncology product candidate anetumab ravtansine (BAY 949343) did not meet the primary endpoint of progression-free survival in recurrent malignant pleural mesothelioma (MPM) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news